Dianthus Therapeutics, Inc.
107.04USD
-2.0900 (-1.92%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | 2.8M | 6.2M | 2.0M | 1.8M | 1.7M |
| Q1 | — | — | 874.0K | 1.2M | — | — |
| Q2 | — | — | 1.9M | 193.0K | — | — |
| Q3 | 1.2M | 924.0K | 2.2M | 396.0K | 317.7K | — |
| Q4 | — | 457.0K* | 1.3M* | 284.0K* | 302.8K | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.905 | -1.41 | -2.55 | -4.20 | -3.83 | -4.62 |
| Q1 | -.726 | -.225 | -.540 | -.820 | -.850 | — |
| Q2 | -.540 | -.354 | -.510 | -.880 | -.900 | — |
| Q3 | -.247 | -.630 | -.740 | -.970 | -.950 | — |
| Q4 | -.321* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.342* |
| -.854* |
| -1.67* |
| -1.13 |
| — |